Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Nature ; 571(7764): 284-288, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-31263273

RESUMEN

Hedgehog signalling is fundamental to embryonic development and postnatal tissue regeneration1. Aberrant postnatal Hedgehog signalling leads to several malignancies, including basal cell carcinoma and paediatric medulloblastoma2. Hedgehog proteins bind to and inhibit the transmembrane cholesterol transporter Patched-1 (PTCH1), which permits activation of the seven-transmembrane transducer Smoothened (SMO) via a mechanism that is poorly understood. Here we report the crystal structure of active mouse SMO bound to both the agonist SAG21k and to an intracellular binding nanobody that stabilizes a physiologically relevant active state. Analogous to other G protein-coupled receptors, the activation of SMO is associated with subtle motions in the extracellular domain, and larger intracellular changes. In contrast to recent models3-5, a cholesterol molecule that is critical for SMO activation is bound deep within the seven-transmembrane pocket. We propose that the inactivation of PTCH1 by Hedgehog allows a transmembrane sterol to access this seven-transmembrane site (potentially through a hydrophobic tunnel), which drives the activation of SMO. These results-combined with signalling studies and molecular dynamics simulations-delineate the structural basis for PTCH1-SMO regulation, and suggest a strategy for overcoming clinical resistance to SMO inhibitors.


Asunto(s)
Membrana Celular/química , Proteínas Hedgehog/agonistas , Transducción de Señal/efectos de los fármacos , Receptor Smoothened/agonistas , Receptor Smoothened/metabolismo , Esteroles/farmacología , Animales , Sitios de Unión , Técnicas Biosensibles , Dominio Catalítico/efectos de los fármacos , Membrana Celular/metabolismo , Colesterol/química , Colesterol/metabolismo , Colesterol/farmacología , Proteínas Hedgehog/metabolismo , Ligandos , Ratones , Modelos Moleculares , Simulación de Dinámica Molecular , Receptor Patched-1/antagonistas & inhibidores , Receptor Patched-1/metabolismo , Conformación Proteica , Estabilidad Proteica , Anticuerpos de Cadena Única/inmunología , Receptor Smoothened/antagonistas & inhibidores , Receptor Smoothened/química , Esteroles/química , Esteroles/metabolismo , Proteínas de Xenopus/química
2.
J Dermatol ; 46(6): 507-514, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31038235

RESUMEN

Skin adnexal cancers (SAC) are a heterogeneous group of rare malignancies with histological differentiation towards epithelial adnexa, which lack effective systemic treatments. The aim of this work is to identify any potentially druggable genomic alterations for possible targeted therapies. Cases of primary or recurrent/metastatic (RM) SAC between 2002 and 2014 were identified by searching the institutional cancer registration database. Histological sections of all referral cases were reviewed by a dedicated pathologist to confirm diagnosis. Immunohistochemistry was performed to assess the expression of androgen receptors (AR) and human epidermal growth factor receptor type 2 (HER2). Targeted next-generation sequencing (T-NGS) was performed to identify targetable mutations (panel of 50 genes analyzed by Cancer Hotspot Panel, Ion-Torrent Personal Genome Machine). Mutational analysis of the PTCH1 gene not present in the T-NGS panel was assessed by Sanger sequencing. A total of 45 cases with available histological samples were identified (35 primary, 10 RM). The most frequent histological type was porocarcinoma (n = 12). Globally, 14 cases (31%) were AR+ (6/10 RM, 60%; 8/35 primary, 23%). HER2 was shown as 2+ in eight of 42 (19%) cases (2/9 RM, 22%; 6/33 primary, 18%). DNA was adequate for T-NGS analysis in 25 cases. In the majority of cases (17 cases, 68%) at least one mutation in oncogenes or tumor suppressor genes was found: the most frequent ones involved TP.53 (13 cases, 76% of mutated SAC) and PIK3CA (three cases, 18%). The rate of PTCH1 mutation was 30%. These findings support the use of molecular screening in patients with advanced SAC.


Asunto(s)
Biomarcadores de Tumor/genética , Recurrencia Local de Neoplasia/genética , Neoplasias de Anexos y Apéndices de Piel/genética , Neoplasias de las Glándulas Sebáceas/genética , Neoplasias de las Glándulas Sudoríparas/genética , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/antagonistas & inhibidores , Fosfatidilinositol 3-Quinasa Clase I/antagonistas & inhibidores , Fosfatidilinositol 3-Quinasa Clase I/genética , Análisis Mutacional de ADN , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Masculino , Terapia Molecular Dirigida/métodos , Mutación , Tasa de Mutación , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/prevención & control , Neoplasias de Anexos y Apéndices de Piel/tratamiento farmacológico , Neoplasias de Anexos y Apéndices de Piel/patología , Receptor Patched-1/antagonistas & inhibidores , Receptor Patched-1/genética , Receptor ErbB-2/antagonistas & inhibidores , Receptor ErbB-2/genética , Estudios Retrospectivos , Neoplasias de las Glándulas Sebáceas/tratamiento farmacológico , Neoplasias de las Glándulas Sebáceas/patología , Neoplasias de las Glándulas Sudoríparas/tratamiento farmacológico , Neoplasias de las Glándulas Sudoríparas/patología , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Proteína p53 Supresora de Tumor/genética
3.
Cell Physiol Biochem ; 48(4): 1416-1432, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30064125

RESUMEN

BACKGROUND/AIMS: Adipocyte-derived exosomes (ADEs) stimulate the activation of macrophages and contribute to the development of insulin resistance. Sonic Hedgehog (Shh) is an exosome-carrying protein and stimulates macrophages to secrete inflammatory cytokines. However, the impact of ADEs carrying Shh on the pro-inflammatory activation of macrophages and consequently, adipocyte insulin resistance is unclear. METHODS: 3T3-L1 adipocytes were cultured with high glucose and insulin to imitate the pathogeny of insulin resistance. ADEs were isolated from conditioned media of 3T3-L1 adipocytes via differential ultracentrifugation. We explored the role of ADEs carrying Shh in the polarization of macrophages by flow cytometry. Western blot and electrophoretic mobility shift assay (EMSA) were performed to determine the activation of Shh-mediated signalling pathways. The effects of ADE-treated macrophages on adipocyte insulin signalling were studied by Western blot. RESULTS: We found that circulating Shh-positive exosomes were increased in type 2 diabetes patients. High glucose and insulin increased the secretion of Shh-positive ADEs. The ADEs carrying Shh induced pro-inflammatory or M1 polarization of bone marrow-derived macrophages (BMDM) and RAW 264.7 macrophages. Inhibitors of Ptch and PI3K blocked the M1 polarization induced by ADEs, which suggests that ADEs carrying Shh mediated M1 macrophage polarization through the Ptch/PI3K signalling pathway. ADE-treated RAW 264.7 macrophages were subsequently used to assess the effect on insulin signalling in adipocytes. Using a co-culture assay, we showed that both ADE-treated macrophages and exosomes from these macrophages could decrease the expression of insulin-resistant substrate-1 (IRS-1) and hormone-sensitive lipase (HSL) in adipocytes. Inhibitors of Ptch and PI3K blocked the down-regulation of IRS-1 and HSL induced by ADE-treated macrophages. CONCLUSION: Together, these data indicate that ADEs carrying Shh induce the M1 polarization of macrophages, which contributes to insulin resistance in adipocytes through the Ptch/PI3K pathway.


Asunto(s)
Diabetes Mellitus Tipo 2/patología , Exosomas/metabolismo , Proteínas Hedgehog/metabolismo , Receptor Patched-1/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Células 3T3-L1 , Adipocitos/citología , Adipocitos/metabolismo , Animales , Diabetes Mellitus Tipo 2/metabolismo , Proteínas Hedgehog/antagonistas & inhibidores , Proteínas Hedgehog/genética , Humanos , Proteínas Sustrato del Receptor de Insulina/metabolismo , Resistencia a la Insulina , Macrófagos/citología , Macrófagos/inmunología , Macrófagos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Receptor Patched-1/antagonistas & inhibidores , Células RAW 264.7 , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Transducción de Señal
4.
Exp Mol Med ; 49(12): e412, 2017 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-29244790

RESUMEN

This study aimed to investigate the effect of Patched-1 (PTC1) and PTC2 silencing in a rat model, on Hedgehog (Hh) pathway-mediated recovery from spinal cord injury (SCI). An analytical emphasis on the relationship between the sonic hedgehog (Shh) pathway and nerve regeneration was explored. A total of 126 rats were divided into normal, sham, SCI, negative control (NC), PTC1-RNAi, PTC2-RNAi and PTC1/PTC2-RNAi groups. The Basso, Beattie and Bresnahan (BBB) scale was employed to assess hind limb motor function. Quantitative real-time polymerase chain reaction and western blotting were performed to examine the mRNA and protein levels of PTC1, PTC2, Shh, glioma-associated oncogene homolog 1 (Gli-1), Smo and Nestin. Tissue morphology was analyzed using immunohistochemistry, and immunofluorescent staining was conducted to detect neurofilament protein 200 (NF-200) and glial fibrillary acidic protein (GFAP). The PTC1/PTC2-RNAi group displayed higher BBB scores than the SCI and NC groups. Shh, Gli-1, Smo and Nestin expression levels were elevated in the PTC1/PTC2-RNAi group. PTC1 and PTC2 mRNA and protein expression was lower in the PTC1/PTC2-RNAi group than in the normal, sham and SCI groups. Among the seven groups, the PTC1/PTC2-RNAi group had the largest positive area of NF-200 staining, whereas the SCI group exhibited a larger GFAP-positive area than both the normal and the sham groups. The Shh pathway may provide new insights into therapeutic indications and regenerative recovery tools for the treatment of SCI. Activation of the Hh signaling pathway by silencing PTC1 and PTC2 may reduce inflammation and may ultimately promote SCI recovery.


Asunto(s)
Terapia Genética , Inflamación/genética , Receptor Patched-1/genética , Receptor Patched-2/genética , Traumatismos de la Médula Espinal/genética , Animales , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/genética , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Proteínas Hedgehog/genética , Humanos , Inflamación/patología , Inflamación/terapia , Lentivirus/genética , Nestina/genética , Receptor Patched-1/antagonistas & inhibidores , Receptor Patched-2/antagonistas & inhibidores , Ratas , Regeneración/genética , Transducción de Señal/genética , Receptor Smoothened/genética , Médula Espinal/patología , Traumatismos de la Médula Espinal/patología , Traumatismos de la Médula Espinal/terapia , Proteína con Dedos de Zinc GLI1/genética
5.
Exp Cell Res ; 355(1): 9-17, 2017 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-28365245

RESUMEN

Aberrant activations of Hedegehog (Hh) signaling were found in hepatocellular carcinoma (HCC) and some other cancer types. However, the details have not been completely understood and the underlying mechanism remains unclear. Here we reported that miR-1249 transcription in HCC cells was regulated through direct binding to the conserved sequences in miR-1249 promoter region by Gli1, which functions as a transcription factor and is a component in the Hh signaling pathway. Interestingly, expression of tumor suppressor PTCH1, which is another component of the Hh signaling pathway, was inhibited by miR-1249 through targeting its 3'-untranslated region. Down-regulation of PTCH1 further enhanced the downstream effects mediated by Gli1. In consistent with these findings, miR-1249 expression level was correlated with degree of prognosis (p=0.005) in HCC patients. Taken together, our results suggested the existence of a positive feedback loop comprised of Gli1, miR-1249 and PTCH1. During the process of HCC progression, this positive feedback loop could be continuously activated to enhance tumor cell growth, migration and invasion.


Asunto(s)
Carcinoma Hepatocelular/genética , Regulación Neoplásica de la Expresión Génica/genética , Neoplasias Hepáticas/genética , MicroARNs/genética , Transducción de Señal/genética , Carcinoma Hepatocelular/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/genética , Perfilación de la Expresión Génica , Humanos , Neoplasias Hepáticas/metabolismo , MicroARNs/metabolismo , MicroARNs/farmacología , Receptor Patched-1/antagonistas & inhibidores , Receptor Patched-1/genética , Receptor Patched-1/metabolismo , Células Tumorales Cultivadas
6.
Actas Dermosifiliogr ; 107(9): 740-750, 2016 Nov.
Artículo en Inglés, Español | MEDLINE | ID: mdl-27436804

RESUMEN

A wide range of treatments is now available for nonmelanoma skin cancer, including 5-fluorouracil, ingenol mebutate, imiquimod, diclofenac, photodynamic therapy, methotrexate, cetuximab, vismodegib, and radiotherapy. All are associated with high clinical and histologic response rates. However, some tumors do not respond due to resistance, which may be primary or acquired. Study of the resistance processes is a broad area of research that aims to increase our understanding of the nature of each tumor and the biologic features that make it resistant, as well as to facilitate the design of new therapies directed against these tumors. In this second article, having covered the topical treatments of nonmelanoma skin cancer, we review resistance to other nonsurgical treatments, such as monoclonal antibodies against basal and squamous cell carcinomas, intralesional chemotherapy, photodynamic therapy, and radiotherapy.


Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma/tratamiento farmacológico , Resistencia a Antineoplásicos , Fotoquimioterapia , Neoplasias Cutáneas/tratamiento farmacológico , Anilidas/administración & dosificación , Anilidas/farmacología , Anilidas/uso terapéutico , Células Presentadoras de Antígenos/efectos de los fármacos , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/farmacología , Antimetabolitos Antineoplásicos/uso terapéutico , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacología , Carcinoma/genética , Carcinoma/radioterapia , Cetuximab/administración & dosificación , Cetuximab/farmacología , Cetuximab/uso terapéutico , Ensayos Clínicos como Asunto , Terapia Combinada , Resistencia a Antineoplásicos/fisiología , Receptores ErbB/antagonistas & inhibidores , Humanos , Inyecciones Intralesiones , Queratoacantoma/tratamiento farmacológico , Metaanálisis como Asunto , Metotrexato/administración & dosificación , Metotrexato/farmacología , Metotrexato/uso terapéutico , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/fisiología , Células Madre Neoplásicas/efectos de los fármacos , Receptor Patched-1/antagonistas & inhibidores , Fármacos Fotosensibilizantes/administración & dosificación , Fármacos Fotosensibilizantes/farmacología , Fármacos Fotosensibilizantes/uso terapéutico , Piridinas/administración & dosificación , Piridinas/farmacología , Piridinas/uso terapéutico , Tolerancia a Radiación/genética , Tolerancia a Radiación/fisiología , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/radioterapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA